ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EPIX

ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline…

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma#SHAREHOLDER…

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma #Biogen #Earnings #Review…

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Royalty Pharma: Delivering Growth With A Positive Story Ahead #Royalty #Pharma #Delivering #Growth #Positive #Story #Ahead

US pharma giant Merck backs healthcare marketplace HD in Southeast Asia

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry.…

Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript

Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript #Astellas #Pharma #ALPMF #Earnings #Call #Transcript

Astellas Pharma Inc. 2024 Q3 – Results – Earnings Call Presentation (OTCMKTS:ALPMF)

This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of…

Terns Pharma: I Don't See The Positioning

Terns Pharma: I Don't See The Positioning #Terns #Pharma #Don039t #Positioning

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade) (NYSE:MRK)

This article was written by Follow Leo Nelissen is an analyst focusing on major economic developments…

Verona Pharma stock soars to all-time high of $51.88 By Investing.com

In a remarkable display of market confidence, Verona Pharma (NASDAQ:)’s stock has surged to an all-time…

Royalty Pharma: Key Strategic Updates To Be Priced In

Royalty Pharma: Key Strategic Updates To Be Priced In #Royalty #Pharma #Key #Strategic #Updates #Priced

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article was written by Follow With over two decades of dedicated experience in investment, Allka…

3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025 By Investing.com

Investing.com — Bernstein analysts are optimistic about the European pharmaceutical sector as it heads into 2025, despite…

Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters

(Reuters) – Gilead Sciences (NASDAQ:) said on Saturday that it entered into a partnership with Denmark’s…

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

— Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral…

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug…

Abbott Laboratories Inventory: A Future-Pushed Pharma Model With A Sturdy Pipeline (NYSE:ABT)

This article was written by Follow The Future Investor with Albert Anthony is an author concept…